Even before its billionaire owner made recent headlines by endorsing an antisemitic post and hurling an expletive at advertisers, biopharma companies had begun to find different uses for their advertisement budgets.
Even before its billionaire owner made recent headlines by endorsing an antisemitic post and hurling an expletive at advertisers, biopharma companies had begun to find different uses for their advertisement budgets.